Hussein Tawbi

59PUBLICATIONS
432CO-AUTHORS
Gene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsNeurology and neuromuscular diseasesCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (59)

|Aug 12, 2026
COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

|Apr 21, 2026
Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: A phase I/II study.

|Jan 15, 2026
Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma.

David S Moura, Jesus Lopez-Marti, Hussein Tawbi

|Nov 27, 2025
Soluble immune factor profiles in blood and CSF associated with LRRK2 mutations and Parkinson's disease.

Roshni Jaffery, Yuhang Zhao, Sarfraz Ahmed

|Oct 18, 2025
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.

Georgina V Long, Charlie Garnett-Benson, Sonia Dolfi

|Sep 12, 2025
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047.

Meredith M Regan, Paolo A Ascierto, Evan J Lipson

Pageof 10

Frequent Collaborators

17 joint publications

Michael A Davies

16 joint publications

Georgina V Long

16 joint publications

Paolo Antonio Ascierto

15 joint publications

Sapna Patel